Dynamic assays of inhibin B and oestradiol following buserelin acetate administration as predictors of ovarian response in IVF.
The study was designed to examine whether dynamic measurements of inhibin B and oestradiol following single administration of buserelin acetate were correlated with the ovarian response to stimulation in IVF. A total of 37 patients undergoing IVF treatment was studied when the long protocol was started in the early follicular phase. Blood samples were taken twice: on day 2 of the menstrual cycle, before the first s.c. administration of buserelin acetate 0.5 mg and on day 3, 24 h later. Inhibin B and oestradiol concentrations were compared with the ovarian response to stimulation. The ovarian response was defined in two ways: 'number of oocytes/total recombinant (r) follicle stimulating hormone (FSH) dose'; and 'square-root (number of follicles/total rFSH dose)'. The following measurements were highly correlated with the ovarian response to stimulation: increase in oestradiol (day 3-day 2 oestradiol concentration) [correlation coefficient (r) = 0.68, P: < 0.0001] and sum of inhibin B (day 2 + day 3 inhibin B concentrations) (r = 0.6, P: < 0.0001). Age and basal concentrations of FSH and inhibin B were inferior to the above measurements in terms of correlation with the ovarian response. In conclusion, dynamic measurements of inhibin B and oestradiol following single administration of buserelin acetate were highly correlated with the ovarian response to stimulation for IVF treatment.
Ravhon
A
A
IVF Unit, Department of Reproductive Medicine and Science, Imperial College School of Medicine, Hammersmith Hospital, London, UK.
Lavery
S
S
Michael
S
S
Donaldson
M
M
Margara
R
R
Trew
G
G
Winston
R
R
D000328:Adult; D002064:Buserelin / Q000627:therapeutic use*; D002452:Cell Count; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000097:blood*; D005260:Female; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage / Q000627:therapeutic use; D005544:Forecasting; D006801:Humans; D007247:Infertility, Female / Q000473:pathology / Q000628:therapy; D009865:Oocytes / Q000473:pathology; D006080:Ovarian Follicle / Q000473:pathology; D010053:Ovary / Q000187:drug effects* / Q000503:physiopathology*; D010455:Peptides / Q000097:blood*; D029584:Prostatic Secretory Proteins; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
D005300:Fertility Agents, Female; D010455:Peptides; D029584:Prostatic Secretory Proteins; D011994:Recombinant Proteins; C043076:beta-microseminoprotein; D004958:Estradiol; D005640:Follicle Stimulating Hormone; D002064:Buserelin